Results 191 to 200 of about 75,950 (311)

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Racial Differences in Prenatal Cannabis Screening Among Women at Elevated Risk for Substance Use and Sexually Transmitted Infections. [PDF]

J Midwifery Womens Health
Countryman K, Sen A, Chen D, Zlotnick C, Mmeje O, Gold KJ, Tzilos Wernette G.   +6 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Polydrug use with opioid involvement: Results from a national sample of U.S. civilians aged 12 years or older. [PDF]

PLoS One
Ding K, Bista S, Welter T, Wheeler KK, Smith GA, Yang J.   +5 more
europepmc   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Marijuana use and its association with unhealthy weight control and muscle-enhancing behaviors among sexual minority men in the United States: a cross-sectional analysis. [PDF]

J Cannabis Res
Ibeh C, Zhao Y, Tran A.
europepmc   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Causal Mediation Analysis for Effect Heterogeneity. [PDF]

Obs Stud
Zhang J, Valeri L.
europepmc   +1 more source

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, EarlyView.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source